Home» Renovo Appoints Business Development Director
Renovo Appoints Business Development Director
9th July 2001
Renovo today announced the appointment of Mr Robin (Rob) Cridland as Business Development Director from 1st September 2001.
Rob (33) joins Renovo from Glaxo SmithKline plc, where he is currently Vice President Corporate Development, a role he has fulfilled since the merger of GlaxoWellcome and SmithKline Beecham in December 2000.
Prior to this, Rob ran successively the Group Financial Investigations team (fulfilling a key planning and execution role in the merger) and the Research and Genetics Projects team at GlaxoWellcome plc, where he structured and negotiated transactions, alliances and partnerships and developed valuation techniques and structuring guidelines to assist with project prioritisation and negotiation. As well as traditional biotech alliances Rob also advised on the successful spin out of Maxygen and the formation of the SNP Consortium on behalf of GW. Prior to joining GW, Rob worked as an investment banker at Enskilda Securities in London and a Consultant/Auditor for Coopers and Lybrand. Rob has a first class MA in Natural Science (Biology) from the University of Oxford and is a member of the ICAEW.
At Renovo Rob will be responsible for all aspects of Business Development, including out licensing, in licensing, partnerships, alliances and will additionally oversee Renovo's finances.
Professor Mark Ferguson, CEO of Renovo commented, "We are delighted to welcome Rob Cridland to Renovo, where his extensive experience of Biotech/Pharmaceutical alliances and collaborations will be a tremendous asset as Renovo moves in to the next phase of its development. Rob has clearly the ability, experience and background to assist with Renovo's future development: his appointment is particularly timely given our early clinical and pre-clinical successes". In a short time Renovo has built an outstanding team of Clinicians and Scientists to focus on developing effective new medicines to prevent scarring or accelerate healing at all body sites. Renovo has already obtained approval and commenced two important clinical studies, with a further portfolio of pre-clinical development and platform technologies well advanced.
Renovo Limited is a UK Biotechnology Spin out Company form the University of Manchester, founded by Professor Mark Ferguson and Dr Sharon O'Kane, which received US$12M in first round financing from Atlas Venture and JP Morgan Partners (formerly Chase Capital Partners) in October 2000. Renovo is developing Pharmaceutical products, which will allow wounds to heal rapidly and with no scars: Renovo aims for Rapid Repair and Regeneration. Renovo's innovative products and technologies build on a portfolio of over 300 worldwide patents and patent applications, fuelling a rich clinical and pre-clinical pipeline and an innovative platform in wound genomics and proteomics. Renovo Limited is housed in the new Manchester Incubator Building and staffed by approximately 35 outstanding Scientists and Clinicians.
Printer-friendly version